

U.S. Patent Application No. 10/555,246
Response to Restriction Requirement and
Election of Species Requirement dated April 16, 2008
Reply to Office Action of March 17, 2008

RECEIVED
CENTRAL FAX CENTER

APR 16 2008

REMARKS/ARGUMENTS

Reconsideration and continued examination of the above-identified application are respectfully requested.


At page 2 of the Office Action, the Examiner is requesting that the applicant elect from one of two groups as follows:

- I. Claims 1-10 and 15-19, drawn to an agent for protecting cardiac damage, wherein the agent contains an effective amount of at least one protease inhibitor and is administered intravenously or orally.
- II. Claims 11-14, drawn to a method for treating arrhythmia, cardiac desmoplasia, and/or heart-failure.

To be responsive, the applicants elect, without traverse, Group II, claims 11-14, drawn to a method for treating arrhythmia, cardiac desmoplasia, and/or heart-failure. Further, regarding the election of species requirement, the applicants elect heart-failure as the single and specific disease to be treated; Suc-Val-pro-L-Phe^P(OPh)₂ for the protease inhibitor; and carboxymethyl cellulose for the carrier. Of the elected invention, claims 11-14 read on the elected species.

If there are any fees due in connection with the filing of this response, please charge the fees to Deposit Account No. 50-0925. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such extension is requested and should also be charged to said Deposit Account.

Respectfully submitted,


Luke A. Kilyk
Reg. No. 33,251

U.S. Patent Application No. 10/555,246
Response to Restriction Requirement and
Election of Species Requirement dated April 16, 2008
Reply to Office Action of March 17, 2008

**RECEIVED
CENTRAL FAX CENTER**

APR 16 2008

Atty. Docket No. 3190-084
KILYK & BOWERSOX, P.L.L.C.
400 Holiday Court, Suite 102
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720